LIFE: Lifecare ASA Q4 2025 results
Bergen, Norway, 3 March 2026 – Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), today publishes its Q4 2025 financial report and operational update.
Highlights:
- System-level validation milestone achieved
- Manufacturing reproducibility established
- Longevity study validates biocompatibility and functional coherence
- Regulatory foundation strengthened
- Financing secured to support near-term operations
Q4 2025 marked a decisive transition for Lifecare – from validating a technology concept to demonstrating reproducible, system-level execution of a fully integrated implantable Continuous Glucose Monitoring (CGM) platform.
During the quarter, Lifecare confirmed in vivo operation of its fully integrated, wireless dual-cavity implant manufactured under the updated production protocol. For the first time, implants from a reproducible production batch tracked glucose behaviour inside living tissue without calibration, smoothing or post-processing. This milestone represents a clear shift in risk profile: from feasibility validation to controlled execution and optimisation.
The results from the ongoing longevity study demonstrate coherent signal behaviour aligned with physiological glucose changes, confirm biocompatibility, and validate the integrity of our complete implant architecture in real biological conditions. Together with CE marking of the electronics module and continued regulatory progress toward first-in-human studies, these achievements materially strengthen the foundation of Lifecare’s platform.
From a strategic perspective, Lifecare has now demonstrated that its proprietary osmotic sensing principle functions not only in laboratory and proof-of-concept settings, but as a fully integrated, implantable and reproducibly manufactured system. The remaining development work is focused on optimisation, regulatory execution and commercial scale-up.
Financially, 2025 reflects continued investment in engineering, manufacturing readiness and regulatory preparation. At year-end, the company operated under a bridge financing structure pending completion of the rights issue in January 2026, which secured immediate operational continuity. Further development, including initiation of the CE trial and progression toward human market launch in 2027, remains dependent on additional capital. The warrant programs in March and June 2026 represent important funding opportunities to support this next phase.
Importantly, the technical progress achieved during Q4 and early 2026 has strengthened external confidence in the platform. The combination of reproducible manufacturing, in vivo validation, regulatory advancement and intellectual property development has positioned Lifecare in a fundamentally stronger strategic position than one year ago.
Lifecare now moves forward with clear priorities: progressing regulatory approvals for first-in-human trials, further refining implant performance and system stability, advancing the veterinary pathway, and securing the capital required to execute on the commercial roadmap.
Q4 2025 represents more than continued development. It marks the point at which Lifecare’s implant platform has transitioned from validated concept to operational system – actively building the foundation for long-term commercial realisation.
Results presentation
CEO Joacim Holter and CFO Renete Kaarvik will present the results live on webcast today at 10:00 CET.
To access the webcast Join the meeting here.
A recording of the webcast will be available on our website after the event.